Theravance (THRX) Price Target Lifted to $17 at BofA/Merrill Lynch
Tweet
Share
E-mailGet Alerts THRX Hot Sheet
Price: $4.06 --0%
Rating Summary:
6 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
6 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
BofA/Merrill Lynch raised its price target on Theravance Inc. (NASDAQ: THRX) to $17.00 (from $15.00) following Q4 results, but maintained a Neutral rating. The firm notes US and ex-US trends are strengthening.
Analyst Steve Byrne raised their ex-US peak to $1.2 billion from $1 billion to equal US peak.
For an analyst ratings summary and ratings history on Theravance Inc. click here. For more ratings news on Theravance Inc. click here.
Shares of Theravance Inc. closed at $15.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MarineMax (HZO) PT Lowered to $35 at Stifel
- Zomato Limited (ZOMATO:IN) PT Raised to INR240 at Goldman Sachs
- Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
